[go: up one dir, main page]

WO2015051337A3 - Méthodes de traitement de troubles gastro-intestinaux - Google Patents

Méthodes de traitement de troubles gastro-intestinaux Download PDF

Info

Publication number
WO2015051337A3
WO2015051337A3 PCT/US2014/059190 US2014059190W WO2015051337A3 WO 2015051337 A3 WO2015051337 A3 WO 2015051337A3 US 2014059190 W US2014059190 W US 2014059190W WO 2015051337 A3 WO2015051337 A3 WO 2015051337A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
gastrointestinal disorders
treating gastrointestinal
treating
decreased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/059190
Other languages
English (en)
Other versions
WO2015051337A2 (fr
Inventor
Shanthi Srinivasan
Bindu CHANDRASEKHARAN
Malu Tansey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2015051337A2 publication Critical patent/WO2015051337A2/fr
Publication of WO2015051337A3 publication Critical patent/WO2015051337A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement d'un trouble gastro-intestinal associé à une diminution de la survie des cellules nerveuses entériques et de la motilité des cellules du côlon.
PCT/US2014/059190 2013-10-04 2014-10-03 Méthodes de traitement de troubles gastro-intestinaux Ceased WO2015051337A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886913P 2013-10-04 2013-10-04
US61/886,913 2013-10-04

Publications (2)

Publication Number Publication Date
WO2015051337A2 WO2015051337A2 (fr) 2015-04-09
WO2015051337A3 true WO2015051337A3 (fr) 2015-11-19

Family

ID=52779310

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059190 Ceased WO2015051337A2 (fr) 2013-10-04 2014-10-03 Méthodes de traitement de troubles gastro-intestinaux

Country Status (1)

Country Link
WO (1) WO2015051337A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016275149A1 (en) * 2015-06-12 2018-01-04 Georgia State University Research Foundation Compositions and methods for treating opioid tolerance
CN106800597B (zh) * 2015-11-26 2021-07-16 上海佳文英莉生物技术有限公司 一种中和促细胞程序性坏死抗体的蛋白及其应用
WO2017106363A1 (fr) * 2015-12-14 2017-06-22 Parkinson's Institute Affinement du diagnostic et du traitement de troubles neurologiques complexes à plusieurs symptômes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20080187509A1 (en) * 2000-03-02 2008-08-07 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-alpha related disorders
US20080269123A1 (en) * 2006-04-03 2008-10-30 Rong Li Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187509A1 (en) * 2000-03-02 2008-08-07 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-alpha related disorders
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20080269123A1 (en) * 2006-04-03 2008-10-30 Rong Li Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANDRASEKHARAN ET AL.: "Targeted Deletion of Neuropeptide Y (NPY) Modulates Experimental Colitis", PLOS ONE, vol. 3, no. 10, 1 October 2008 (2008-10-01), pages 1 - 11, XP002686674, ISSN: 1932-6203 *
CHANDRASEKHARAN ET AL.: "TNF alpha Inhibitors Attenuate N europe ptide Y (NPY) Expression in the Murine Enteric Nervous System", IMPLICATIONS IN INFLAMMATION AND COLONIC MOTILITY, vol. 18, December 2012 (2012-12-01), pages S93, XP055237213, Retrieved from the Internet <URL:http://journals.lww.com/ibdjournal/Citation/2012/12001/TNF8_Inhibitors_Attenuate_Neuropeptide_Y_NPY_.229.aspx> [retrieved on 20150225] *

Also Published As

Publication number Publication date
WO2015051337A2 (fr) 2015-04-09

Similar Documents

Publication Publication Date Title
IL273979A (en) Methods for the production of adapted natural killer cells and methods of use
IL288265A (en) Production and use of red blood cells
ZA201807001B (en) Acrylic acid, and methods of producing thereof
IL285258A (en) Retinal ganglion cells and their progenitor cells
IL244709A0 (en) Methods for diagnosis and treatment of eosinophilic disorders
EP2983657A4 (fr) Traitement de troubles gastro-intestinaux et d&#39;autres troubles
SG11201703441YA (en) Energy storage devices and methods of production thereof
GB201602491D0 (en) Structures and methods with reduced sensitivity to surface charge
HUE041716T2 (hu) Karbonizálási eljárás és szénszál elõállítási eljárás
PT3022274T (pt) Método para a obtenção de copoliamidas anti-inflamáveis, dos fios de poliamida que podem ser obtidos segundo esse método e aplicação dos referidos fios de poliamida
IL252000A0 (en) New uhmwpe fiber and method for its production
GB2547123B (en) LED vertical chip structure with special coarsening morphology and preparation method therefor
PT2978793T (pt) Poliamida resistente à chama, método de produção da respetiva poliamida resistente à chama e utilização da respetiva poliamida resistente à chama
SG11201507321WA (en) Template assembly and method of producing template assembly
WO2015051337A3 (fr) Méthodes de traitement de troubles gastro-intestinaux
SG11201700971XA (en) Methods to enhance nerve regeneration utilizing neural stem cells and il12p40
WO2015089503A3 (fr) Procédés de traitement de troubles du cerveau ou d&#39;identification de biomarqueurs associés à ceux-ci
AU364660S (en) Extendible pole
IL256875A (en) Epha7-positive stem cells, methods of their preparation and uses thereof
EP3055678A4 (fr) Ensembles d&#39;épreuves et leurs procédés d&#39;exécution et d&#39;utilisation
ZA201701516B (en) Efi ignition module and method of production
CA154515S (en) Bottom filtration header
AU2014902547A0 (en) A method of forming a photovoltaic cell and a photovoltaic cell formed according to the method
HUE043794T2 (hu) Eljárás levezetõk rögzítésére egy elektródelrendezésen energiatároló cella elõállításánál
AU354699S (en) A roof overflow

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850153

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14850153

Country of ref document: EP

Kind code of ref document: A2